The Escalation of the Opioid Crisis

The opioid epidemic has reached alarming heights, with opioid overdose deaths tripling over the past decade. In 2022 alone, the US saw 81,806 opioid-related deaths. This surge has been driven by various waves of opioid misuse, starting with prescription opioids, followed by heroin, synthetic opioids like fentanyl, and most recently, the co-use of stimulants such as methamphetamines and cocaine.

Life Expectancy and Years of Life Lost

The study employed cause-eliminated life tables to estimate the reduction in life expectancy and total YLL due to opioid overdose deaths. The findings are stark: opioid-related deaths in 2022 resulted in an estimated 3.1 million years of life lost, averaging 38 years per death. Nationally, opioid-related mortality reduced life expectancy by 0.67 years in 2022, up from 0.52 years in 2019.

Demographic Disparities

The burden of opioid-related mortality has worsened across all racial and ethnic groups. From 2019 to 2022, life expectancy reductions varied significantly:

• White men: 0.76 years to 0.96 years
• White women: 0.36 years to 0.55 years
• Black men: 0.59 years to 1.1 years
• Black women: 0.27 years to 0.53 years
• Hispanic men: 0.31 years to 0.82 years
• Hispanic women: 0.19 years to 0.31 years
• American Indian/Alaska Native (AI/AN) men: 0.62 years to 1.5 years
• AI/AN women: 0.43 years to 1 year
• Asian men: 0.09 years to 0.2 years
• Asian women: 0.08 years to 0.13 years

These figures indicate a substantial increase in mortality burden, particularly among AI/AN, Black, and Hispanic populations, which now approach or exceed the burden experienced by white Americans.

Polysubstance Use: A Growing Concern

Polysubstance use, especially the co-use of opioids with stimulants like cocaine and methamphetamines, has emerged as a significant factor in opioid-related deaths. In 2022, such combinations were involved in half of all opioid overdose deaths, with variations in predominant drug classes by state and racial/ethnic group.

Geographic Variations

Nearly all states experienced an increase in YLL per capita from 2019 to 2022, with YLL more than doubling in 16 states. West Virginia, Delaware, and Maine saw the highest rates of YLL per capita, while states like Hawaii, Nebraska, and South Dakota reported significantly lower rates.

The COVID-19 Pandemic’s Role

The onset of the COVID-19 pandemic exacerbated the opioid crisis, with disruptions to social, economic, and healthcare systems contributing to the rise in fatal overdoses. The study period coincides with the pandemic years, highlighting the compounded public health challenges.

Implications for Policy and Public Health

Despite significant investments to curb the opioid crisis, opioid overdose mortality has continued to rise. The study underscores the urgent need for transformative policy approaches that address the underlying causes of opioid misuse, enhance access to treatment, and tackle the growing issue of polysubstance use.

Conclusion

The latest findings on the opioid crisis reveal a worsening scenario with significant implications for life expectancy and public health in the US. As the crisis evolves, particularly with the rise in polysubstance use, comprehensive and equitable strategies are crucial to mitigate its impact and save lives. The study calls for renewed and robust efforts to address this ongoing public health emergency.

References

Hébert, A. H., & Hill, A. L. (2024). Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019 to 2022. The Lancet Regional Health – Americas, 36, 100813. https://doi.org/10.1016/j.lana.2024.100813

The post US Opioid Crisis: Life Expectancy Drops, Polysubstance Use on the Rise, Study Finds appeared first on Mindheal.

A Comprehensive Study to Understand Bystander Behavior

A recent study published in the Harm Reduction Journal by Thompson et al. delved deep into the dynamics of bystander responses to opioid overdoses in Connecticut, aiming to identify effective policy options for enhancing the impact of GSLs. This study utilized a systems-level approach, engaging a diverse group of stakeholders through six Group Model Building (GMB) workshops. Participants included medical professionals, community members, first responders, and individuals with lived experience of witnessing overdoses.

Key Findings: The Dynamics of Bystander Behavior

The study’s qualitative system dynamics (SD) model revealed intricate feedback loops and systemic interactions that influence bystander behavior. The model highlighted four key narrative domains:

1. Overdose, Calling 911, and First Responder Burnout: This narrative explored the complex interplay between calling 911 during an overdose and the resulting impact on first responders. Reinforcing feedback loops showed that while calling 911 saves lives, the increased demand on first responders can lead to burnout and stigmatization of individuals with opioid use disorder (OUD), ultimately discouraging future 911 calls.
2. Naloxone Use, Acceptability, and Linking Patients to Services: This narrative underscored the importance of naloxone, a life-saving drug that reverses opioid overdoses. The study found that while increased naloxone use can prevent deaths, its effectiveness is limited if overdose victims are not linked to treatment services, potentially leading to repeated overdoses.
3. Drug Arrests, Belief in Good Samaritan Laws, and Community Trust in Police: The relationship between law enforcement and the community was a critical factor. The fear of arrest and negative interactions with police can deter bystanders from seeking help during overdoses. Building trust and fostering a culture of harm reduction within law enforcement can significantly improve community willingness to call 911.
4. Bystander Naloxone Use, Community Participation in Harm Reduction, and Cultural Change Towards Carrying Naloxone: This narrative highlighted how successful naloxone administration can encourage broader community participation in harm reduction efforts, promoting a cultural shift towards carrying and using naloxone.

High-Leverage Policy Recommendations

Based on the findings, the study identified nine high-impact strategies categorized into four themes:

1. Naloxone Access & Use: Expanding programs like naloxone “leave behind” initiatives and ensuring that EMS, fire, and police departments carry and administer naloxone.
2. Community-Based Harm Reduction Services & Teams: Enhancing connections between overdose victims and addiction treatment services, implementing recovery navigator programs, and providing services at overdose sites.
3. Safer Drug Use: Establishing safe spaces for drug use and developing smartphone applications that alert others in case of an overdose.
4. Education to Reduce Stigma: Training new law enforcement and emergency department staff to reduce stigma and engaging medical trainees to foster a supportive clinical culture.

Conclusion: Towards a Holistic Approach

The study by Thompson et al. underscores the complexity of addressing opioid overdoses and the critical role of systemic, multifaceted approaches. By understanding the dynamics of bystander behavior and the interplay of various social, structural, and policy factors, policymakers can design more effective strategies to reduce opioid-related deaths. Building trust, expanding access to naloxone, and fostering community participation in harm reduction are key steps towards a more resilient and supportive system for individuals with OUD in Connecticut.

For more in-depth insights and detailed policy recommendations, the full study can be accessed here.

The post Improving Opioid Outcomes: Insights from Connecticut’s Good Samaritan Laws appeared first on Mindheal.

Increasing Access to Essential Treatment

The opioid crisis has led to changes in federal policy aimed at making it easier for doctors to prescribe buprenorphine by removing specialized training requirements and lifting patient limits. Despite these changes, there is still a large gap between the number of people who need buprenorphine and the number who receive it in primary care settings. This study surveyed a representative sample of adults across the country to understand public awareness and attitudes toward receiving opioid addiction treatment from their primary care doctor.

Key Findings

The survey included 1,234 respondents from various backgrounds:

• 56.5% were female, and 43.5% were male
• 11.5% identified as Black, 15.2% as Hispanic or Latino, 68.4% as White, and 4.8% as other or multi-racial

The results showed that a majority of respondents (61.4%) did not know that primary care doctors could prescribe buprenorphine, and 13.3% incorrectly believed that they could not. However, there was strong support for primary care doctors providing opioid addiction treatment, with 53.9% agreeing and 24.9% strongly agreeing that they should.

Comfort with Treatment from Primary Care Doctors

The study also looked at how comfortable people would feel seeking or referring others to their primary care doctor for buprenorphine treatment. Among those who had used opioids:

• 50.6% said they would be very comfortable seeking treatment from their primary care doctor
• 30.7% said they would be somewhat comfortable

Among those who had not used opioids:

• 31.9% said they would be very comfortable referring someone to their primary care doctor for treatment
• 42.0% said they would be somewhat comfortable

Implications and Future Directions

Dr. del Pozo and his team emphasize that increasing public knowledge about the availability of buprenorphine from primary care doctors is essential for expanding access to this life-saving treatment. With around 209,000 primary care doctors across the United States, the healthcare system has a significant opportunity to improve the reach and effectiveness of opioid addiction treatment.

The study highlights the importance of educational campaigns and support for primary care doctors to encourage them to offer buprenorphine treatment. As the fight against the opioid epidemic continues, the role of primary care in providing accessible and comprehensive treatment options will be crucial.

This important research shows the untapped potential of primary care doctors in addressing the opioid crisis with buprenorphine treatment. By raising public awareness and providing support to doctors, the healthcare system can make significant progress in reducing overdose deaths and improving the lives of people with opioid addiction.

For more details, read the full study published in JAMA Network Open here.

The post Few Americans Know PCPs Can Treat Opioid Addiction appeared first on Mindheal.

Mallinckrodt’s Rise and Strategies

From 2006 to 2012, Mallinckrodt dominated the US opioid market, selling nearly 40% of all opioid pills. Despite facing minimal public scrutiny compared to Purdue Pharma, Mallinckrodt’s operations had a profound impact on the opioid crisis. Their baby blue 30 mg oxycodone tablets, marked with “M30,” became so ubiquitous that counterfeits containing fentanyl still plague the streets today.

Despite legal challenges and two bankruptcy filings, Mallinckrodt has continued its operations. The company was ordered to pay $1.7 billion for misleading marketing practices but largely avoided full payment. The internal documents, made public, reveal a sophisticated strategy to influence doctors and shape the discourse around opioid use.

A Coordinated Effort to Influence

Mallinckrodt’s internal documents reveal a variety of tactics designed to increase opioid sales. These included designing continuing medical education (CME) courses, recruiting physicians as influencers, and planting articles in scientific journals. These efforts were aimed at portraying opioids as essential for both acute and chronic pain management, despite the growing addiction crisis.

Contracts with nearly 900 physicians and medical education companies show the extent of Mallinckrodt’s efforts to mold medical opinions. These contracts, totaling millions of dollars, aimed to position extended-release opioids like Exalgo and Xartemis as innovations in pain management. They also worked to mitigate concerns about addiction by promoting concepts like “pseudoaddiction,” where patients’ need for higher doses was framed as a symptom of under-treatment rather than addiction.

Manipulating Medical Education and Opinion

A significant part of Mallinckrodt’s strategy involved creating and funding CME programs. For example, the “Remedies: Focus on Opioid Tolerance” program aimed to educate 10,000 physicians, eventually expanding to reach over 88,000 prescribers. These programs were designed to present Mallinckrodt’s products favorably while downplaying the risks associated with opioid use.

Key opinion leaders (KOLs) played a crucial role in this strategy. Physicians like Michael Brennan and Charles Argoff, who received substantial payments from Mallinckrodt, were instrumental in disseminating the company’s messages. These KOLs helped to normalize the use of high-dose opioids and to frame concerns about addiction as irrational fears or “opioid-phobia.”

Ghostwriting and Publication Planning

Mallinckrodt also engaged in ghostwriting and publication planning, strategically placing articles in medical journals to support their products. Contracts with medical education companies like MedLogix ensured that the company’s preferred narratives were widely disseminated. These ghostwritten articles often presented extended-release opioids as safer alternatives, despite a lack of supporting evidence.

One notable concept promoted by Mallinckrodt was “chronification,” the idea that untreated acute pain leads to chronic pain, which supposedly justified early and aggressive opioid treatment. This concept was featured in review articles and CME programs, further entrenching the use of opioids in pain management.

The Aftermath and Continuing Impact

Despite the scrutiny and legal battles, Mallinckrodt remains a significant player in the opioid market. In 2023, the company reported $262 million in opioid sales, a 25% increase from the previous year. The release of these documents has provided invaluable insight into the corporate strategies that contributed to the opioid crisis.

The tactics revealed in Mallinckrodt’s internal documents highlight the broader issue of pharmaceutical influence on medical practice. By understanding these strategies, we can better address the root causes of the opioid epidemic and develop more effective policies to prevent similar crises in the future.

Conclusion

Mallinckrodt’s story is a stark reminder of the lengths to which pharmaceutical companies will go to protect and expand their market share, often at the expense of public health. The release of these documents underscores the need for greater transparency and accountability in the pharmaceutical industry. As we continue to grapple with the fallout from the opioid crisis, the lessons learned from Mallinckrodt’s playbook will be crucial in preventing future public health disasters.

Source and Authors

This article is based on an in-depth essay published in BMJ by Sergio Sismondo, a professor of Philosophy at Queen’s University in Ontario, Canada, and Maud Bernisson from the Institute for Science in Society at Radboud University, Nijmegen, Netherlands. Sismondo and Bernisson have meticulously analyzed nearly 900 contracts from the 1.3 million internal documents released by Mallinckrodt, revealing the extensive tactics used by the company to shape medical and scientific opinions.

Find More

1. Synthetic Opioids: Crisis 2.0
2. Opioid Overdose Risks
3. First Aid for Opioid Overdose

The post Opioid Crisis Uncovered: Mallinckrodt’s Methods to Sway Medical Practices appeared first on Mindheal.

Below you will find my free retelling of a great article Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. All graphs and tables are also taken from this article, unless otherwise specified.

Opioid Epidemic Today

In 2022, approximately 80,000 people in the US died from opioid-induced respiratory depression (OIRD), accounting for about three-quarters of all drug overdose fatalities. This number has skyrocketed by around 400% over the last ten years, primarily due to the sharp rise in the use of synthetic opioids like fentanyl and its more potent relatives, such as carfentanil. For context, fentanyl is about 224 times more potent than morphine, significantly increasing the risk of respiratory failure and deadly hypoxia.

Opioid-related deaths typically involve individuals with opioid use disorder (OUD), but they can also tragically affect those without OUD who are prescribed opioids. Especially vulnerable are those prescribed high daily doses (over 50 morphine milligram equivalents), or those combining opioids with other substances like benzodiazepines, gabapentinoids, or alcohol. Such people may overdose accidentally due to errors like misinterpreting dosage instructions, self-medicating for additional symptoms, or confusion from age-related cognitive changes.

Demographically, opioid overdose rates are higher among men compared to women across all age and ethnic groups. Additionally, those who are male, younger, white, and born in the US are at a higher risk of suffering from OIRD.

The Legacy of Morphine

In recent years, synthetic opioids have become the primary culprits in opioid-related deaths. By 2021, around 90% of all OIRD fatalities were linked to synthetic opioids. During the period from 2016 to 2021, the overdose death rates from fentanyl alone soared by 279%, climbing from 5.7 per 100,000 to 21.6 per 100,000.

In terms of potency, which reflects the amount of a drug needed to produce a specific effect, fentanyl is about 224 times more potent than morphine and 30-50 times more potent than heroin. Carfentanil, an extremely potent variant, surpasses morphine’s potency by a staggering 10,000 times. It’s crucial to distinguish between potency, which refers to the concentration of a drug required to achieve 50% of its maximum effect (EC50), and efficacy, which is the maximum effect a drug can produce. Beyond a certain point, increasing the dose of a drug will not intensify its effects, which defines its efficacy.

Fentanyl Death Star

Fentanyl, approved by the US Food and Drug Administration (FDA), is widely used in medical settings to manage pain in cancer patients and to provide anesthesia and perioperative analgesia in other clinical scenarios. However, the majority of opioid-induced respiratory depression deaths involving fentanyl in the US are linked to its illicit production rather than misuse of prescribed medications.

Fentanyl is not only cheaper but also easier to synthesize compared to heroin. For instance, the wholesale cost of heroin was around $60,000 per kilogram in 2017, whereas fentanyl cost significantly less at approximately $3,500 per kilogram. Its high potency allows it to be easily concealed and transported, which lowers the risks for those involved in its illegal distribution.

Fentanyl is often sold as counterfeit opioid pain pills that mimic the appearance of medications such as oxycodone, oxycodone/acetaminophen, or hydrocodone/acetaminophen tablets. A grave risk emerges when fentanyl is clandestinely added to stimulants like cocaine or methamphetamine, significantly increasing the danger of OIRD among users who are typically opioid-naive and at a high risk of overdose and death.

US Customs and Border Protection reported a significant increase in illegal fentanyl seizures, with 14,700 tons intercepted in 2022, up from 4,800 tons in 2020. In contrast, heroin seizures decreased from 5,800 tons in 2020 to 1,900 tons in 2022. From 2016 to 2020, fentanyl-related drug trafficking offenses skyrocketed by 1,946%, while offenses involving heroin and oxycodone dropped by 33.2% and 47.1%, respectively. Methamphetamine is the only other drug showing an increase in trafficking offenses during this period, rising by 13.9%. The trend of escalating fentanyl offenses continues, with a 435% increase noted between 2018 and 2022.

Nitazenes: New Opioids

Nitazenes are a category of synthetic opioids that, unlike many others, do not share a structural template with fentanyl. This group includes compounds such as etonitazene, isotonitazene, flunitazene, metonitazine, protonitazene, and 5-aminoisotonitazene. Originally developed for pain relief, none of these substances have been approved for medical use in humans.

Remarkably, nitazenes are estimated to be about 10 to 40 times more potent than fentanyl. Over recent years, the number of deaths associated with these drugs has risen, marking them as a growing threat. A significant challenge in addressing this issue is that nitazenes are often not detected in standard toxicology tests, making it difficult to accurately track their impact.

Since 2019, there have been approximately 2,400 incidents involving illicit nitazenes reported to the US National Forensic Laboratory Information System, highlighting the increasing presence and concern surrounding these potent substances.

Xylazine: False Opioid

Xylazine, commonly known as tranq, tranq-dope, sleep-cut, Philly dope, or zombie, is increasingly being used to adulterate street drugs like cocaine, heroin, methamphetamine, and especially fentanyl. Originally intended for veterinary purposes as an analgesic, sedative, and muscle relaxant, xylazine targets the α-2-adrenergic receptor—similar to the antihypertensive drug clonidine and the muscle relaxant tizanidine. Its effects include central nervous system and respiratory depression, hypotension, hypothermia, and bradycardia, mirroring some opioid effects.

One of the dire consequences of injecting xylazine is the development of severe, necrotic skin ulcerations, which can occur even at sites distant from the injection area. These ulcerations differ from typical infections linked to drug injections. The sedative properties of xylazine allow traffickers to reduce the opioid content in drug mixtures while maintaining similar effects for the user, thereby increasing profitability.

A critical concern with xylazine is that it is not reversed by naloxone, the primary treatment for opioid overdoses, because xylazine is not an opioid. Additionally, xylazine is not detected in routine toxicology screens, making OIRDs involving xylazine particularly perilous and challenging to manage. Moreover, withdrawal symptoms from xylazine cannot be effectively treated with methadone, buprenorphine, or naltrexone, which are standard treatments for OUD.

Given its profound impacts and the complexity of managing overdoses, xylazine has been officially designated as an emerging threat by the Director of the Office of National Drug Control Policy in 2023. Some states, including Ohio and Pennsylvania, are moving to classify xylazine as a controlled substance, even though it is not currently regulated under the Federal US Controlled Substances Act.

Opioid-Induced Respiratory Depression

OIRD is a critical condition that often leads to death due to cardiac arrest, which follows respiratory arrest and asphyxia. This sequence of events is triggered by opioids binding to receptors in the central nervous system (CNS). The early signs of OIRD include lethargy, reduced consciousness, and constricted pupils, progressing to more severe symptoms like unconsciousness, seizures, and respiratory distress—characterized by shallow breathing or slow breathing rates, which can lead to a dangerous drop in oxygen levels (hypoxia).

When hypoxia sets in, immediate intervention is crucial. Brain damage can occur within just 3 to 6 minutes of oxygen deprivation, potentially leading to bradycardia (slow heart rate), other heart rhythm problems, and eventually cardiac arrest and death. This creates a critical, narrow window for first responders or caregivers to act to prevent a fatal outcome.

It’s important to note that the toxic effects of opioids occur only when they enter the bloodstream through ingestion, injection, or inhalation. Direct skin contact with these substances does not cause opioid toxicity. This understanding is vital for effectively managing and responding to incidents of opioid overdose, emphasizing the urgency and methods of response that can save lives in cases of OIRD.

Naloxone: A Key Tool in OIRD

Naloxone is an essential medication used to reverse the life-threatening effects of opioid-induced respiratory depression (OIRD). This includes respiratory depression, sedation, and hypotension. Naloxone works by competing with opioids for binding at µ-, κ-, and δ-opioid receptors in the body, displacing the opioids and quickly reversing their effects.

To be effective, naloxone must reach the opioid receptors promptly and in sufficient concentration to displace opioids from more than 50% of these sites. Treatment of OIRD involves not only administering naloxone but also managing the airway and continuously assessing the person’s oxygenation and ventilation.

Currently, various naloxone formulations are approved, including nasal sprays, prefilled injection devices, and generic options for intravenous (IV), intramuscular (IM), or subcutaneous delivery:

• Nasal sprays: Narcan delivers 2 or 4 mg of naloxone hydrochloride with a bioavailability of 44.2%. Kloxxado, another nasal spray, delivers 8 mg with a bioavailability of 41.6%/47.6%.
• Injectable devices: Zimhi, designed similarly to an EpiPen, contains 5 mg of naloxone in a prefilled syringe for IM or subcutaneous administration. It can be administered through clothing into the thigh.

In 2023, the FDA approved 4-mg intranasal naloxone for over-the-counter, non-prescription use, and a 3-mg dose was also recently approved, making it more accessible in efforts to reduce opioid-related deaths.

Naloxone is a critical medication in reversing opioid-induced respiratory depression (OIRD), with its effectiveness depending on the mode of administration. Intravenous (IV) administration of naloxone acts the fastest, typically within 2 minutes, but requires medical personnel like emergency technicians, paramedics, or nurses. On the other hand, intramuscular (IM) or subcutaneous injections can be administered by minimally trained first responders or even family members, taking effect between 2 and 5 minutes.

Intranasal (IN) administration, while slightly slower than IV, offers a practical solution for rapid deployment in emergencies, especially outside hospital settings. Among the naloxone options, Zimhi, an IM injection, shows a higher maximum plasma concentration (Cmax) and a greater area under the plasma concentration-time curve (AUC) than both the 4-mg IN Narcan and 2-mg/2-mL IM generic naloxone doses. This higher bioavailability means Zimhi achieves faster and higher systemic naloxone levels than lower-dose IM/subcutaneous and IN formulations.

Zimhi is not alone in offering high-dose naloxone for rapid administration; Kloxxado nasal spray delivers an 8-mg dose and reaches more than twice the Cmax of a 4-mg Narcan dose in half the time. These differences are significant in treating OIRDs as demonstrated in preclinical studies and pharmacological modeling, which explore the relationship between naloxone plasma levels and µ-opioid receptor occupancy. For instance, higher doses of naloxone administered to rhesus monkeys showed greater receptor blockade, indicative of effective overdose reversal.

Pharmacokinetic models suggest that higher doses of naloxone can more rapidly reduce µ-opioid receptor occupancy by fentanyl, crucial for reversing toxicity. For example, in conditions simulating a mid-range fentanyl exposure, a 2-mg IM dose of naloxone would reduce receptor occupancy to 50% in about 13.54 minutes, compared to just 4 minutes with a 5-mg dose and even faster with a 10-mg dose. This dose-response relationship holds even at higher fentanyl levels, underscoring the importance of dose in naloxone’s effectiveness.

The information underscores the necessity for potent, rapidly-acting naloxone formulations like Zimhi and Kloxxado in managing the critical window during opioid overdose scenarios, enhancing the chances of saving lives.

Synthetic Opioid Overdose Reversal

Nalmefene: A New Player

While much of the focus in opioid overdose treatment is on naloxone, it’s important to also consider nalmefene, a µ-opioid receptor antagonist that offers a new approach to managing OIRD. Approved by the FDA in 2023 as an intranasal (IN) spray under the brand name Opvee by Indivior Inc., each dose delivers 2.7 mg of nalmefene, with additional doses permissible every 2–5 minutes as needed. Nalmefene is not new to the pharmaceutical world; it was initially approved in 1995 as an injectable, though it was later withdrawn in 2008 due to business reasons.

One of the key advantages of nalmefene over naloxone is its longer half-life—approximately 11.4 hours compared to about 2 hours for IN naloxone—which may enhance its efficacy in sustaining opioid reversal. However, this extended action could also lead to prolonged withdrawal symptoms, which some may view as a disadvantage.

High-Dose Naloxone

Recent simulations and feedback from first responders indicate that multiple doses of traditional naloxone formulations (such as 2 mg intramuscular [IM], 4 mg intranasal [IN], and 8 mg IN, the latter equivalent to 4 mg IM) are often necessary to counteract the severe respiratory depression caused by potent opioids like fentanyl. There is a growing recognition that higher doses (e.g., 5 and 10 mg IM) may offer more effective and swifter antagonism of opioids at the µ-opioid receptor level, leading to quicker reversal of toxicity.

Regarding newer synthetic opioids like nitazenes, naloxone remains a potential antidote due to their opioid-like effects. However, their high potency might necessitate higher or more frequent naloxone dosages, similar to those used in treating fentanyl overdoses. For instance, a study involving emergency department admissions found that patients exposed to non-fentanyl synthetic opioids like brorphine and various nitazenes required more naloxone doses, suggesting these substances may be more potent than fentanyl.

Xylazine, an α2-adrenergic receptor agonist often mixed with opioids, complicates the clinical picture as it does not respond to naloxone, which targets opioid receptors. Thus, while naloxone can reverse the opioid effects in a xylazine-adulterated OIRD, it does not affect the depressive effects caused by xylazine itself. This situation underscores the necessity for hospitalization, where treatment can include IV fluids, intubation, and possibly cardiac interventions.

Given the complexity of these cases, especially when the presence of substances like xylazine may not be initially apparent, it is crucial for all OIRD patients to be transported to a hospital for comprehensive evaluation and appropriate continued care.

Challenges in Opioid Overdose Treatment

The introduction of high-dose naloxone formulations has been generally positive, enhancing the capabilities of first responders in emergency situations involving opioids. However, there are ongoing debates about their necessity. Critics argue that existing data on the number of naloxone doses needed during OIRD interventions are inconclusive and complicated by factors like the presence of sedating drugs and adulterants, questioning whether standard doses are indeed insufficient.

In a 2022 study, the public’s perception of naloxone efficacy, especially after administering the drug, indicated a strong preference for higher doses. Most respondents (87%) felt more confident using an 8-mg IN naloxone spray compared to a 4-mg dose, with 76% preferring to carry the higher dose. This preference was largely driven by beliefs that the higher dose could act faster and more effectively, particularly in communities affected by fentanyl and other synthetic opioids.

When using naloxone to reverse OIRD, certain adverse effects can occur, particularly in individuals with physical dependence on opioids. Notably, while symptoms such as vomiting and aspiration present risks, they are rarely fatal and are considered less critical than addressing the life-threatening effects of an overdose like respiratory depression, unconsciousness, bradycardia, and hypothermia—all of which are reversible with naloxone.

Rare but serious condition is naloxone-induced non-cardiogenic pulmonary edema. This condition may arise from a surge in catecholamines triggered by naloxone, leading to blood volume shifts and increased pulmonary permeability. Although there’s concern that higher doses of naloxone might elevate this risk, studies show mixed results. One study indicated a higher incidence of pulmonary complications with doses above 4.4 mg, while another found no significant correlation between naloxone dose and the occurrence of pulmonary issues or extended hospital stays.

The evolving landscape of opioid abuse, particularly with potent substances like fentanyl and its analogs, often necessitates multiple, higher doses of naloxone. These substances’ potency can mean that a single administration of naloxone may not suffice due to its relatively short half-life, which might require repeated dosing to maintain effectiveness as opioid levels remain high in the body.

Despite the need for higher-dose options, there’s a concern that their availability might overshadow lower-dose formulations, potentially reducing their use. It’s crucial to remember that any naloxone, regardless of the dose, is beneficial. In the context of the ongoing opioid crisis, the adage that “perfect should not be the enemy of good” holds particularly true. The priority should be to enhance accessibility to all forms of naloxone, ensuring that those experiencing an overdose have the best possible chance at recovery. This approach underscores the importance of naloxone as a lifesaving tool, irrespective of the dosage.

Expanding Education in Naloxone Use

Handling Injectable Naloxone: A prevalent concern with naloxone, particularly the injectable type like Zimhi, is the use of needles. This can be daunting for first responders and caregivers, despite its critical role in emergency situations involving opioid-induced respiratory depression (OIRD). While individuals with a history of substance use involving syringes may not find this concerning, others might worry about the complexity of using a traditional syringe. However, devices like Zimhi are designed for ease of use, featuring a needle shield to prevent injuries post-use, which addresses one of the main fears surrounding needle sticks. Education and hands-on demonstrations can significantly help in alleviating these concerns, ensuring that Zimhi is as approachable and straightforward to use as nasal sprays like Kloxxado and Narcan.

Real-world Education and Stigma Challenges: Despite widespread awareness of the opioid crisis, there remains a significant gap in public understanding of naloxone and its application. The stigma surrounding OUD often deters families from obtaining naloxone, for fear of judgment or repercussions regarding insurance or employment. Moreover, the presence of law enforcement at overdose scenes can discourage calls for help due to fears of legal consequences, despite Good Samaritan laws designed to protect those seeking medical aid in such emergencies.

Education plays a crucial role not only in demonstrating how to use naloxone but also in understanding when and how to seek it. Emergency calls should be made immediately before or after administering naloxone, as the patient may require further medical intervention due to the short half-life of naloxone and the long-lasting effects of potent opioids like fentanyl.

Guidelines and Accessibility: The CDC recommends that individuals at risk of an opioid overdose be provided with a naloxone prescription along with their opioid prescription. Risk factors include high opioid dosages, concurrent prescriptions like benzodiazepines, and certain medical conditions. Despite increased naloxone availability over the past two decades, distribution at community pharmacies remains relatively low, underscoring the need for broader access and education.

Expanding naloxone distribution is critical, not only as a lifesaving measure but also as a potential gateway to treatment. Medication-assisted treatment (MAT) options like buprenorphine and methadone are vital components of OUD treatment, and naloxone can serve as a crucial first step on the path to recovery. Increasingly, naloxone is available without a prescription, through pharmacies, community programs, and non-profits, enhancing access.

Data and Advocacy: Real-time data collection on OIRDs through platforms like the Overdose Detection Mapping Application Program (ODmap) provides invaluable information to first responders and public health officials. However, the quality of the data and the participation rate among states can vary, sometimes limiting the effectiveness of response strategies.

Education and advocacy are essential not only for promoting naloxone use but also for integrating it into broader health care strategies that include MAT. With recent changes in prescribing regulations for substances like buprenorphine, more medical professionals, including pharmacists, can engage in this critical aspect of public health.

Moving forward, it is crucial that all FDA-approved naloxone products, whether intranasal or injectable, are made widely available to combat the opioid epidemic effectively. This approach ensures that naloxone remains a cornerstone of emergency responses to OIRD, ultimately saving lives and facilitating long-term recovery solutions.

Conclusion

The emergence of new synthetic opioids represents a significant challenge in the ongoing battle against the opioid epidemic. These substances, often more potent and dangerous than their predecessors, necessitate a multi-faceted approach to drug policy, healthcare response, and public education. As the landscape of opioid misuse continues to evolve, it is critical that our strategies adapt accordingly.

Public education campaigns are essential to raise awareness about the risks of synthetic opioids and to disseminate information on how to respond to overdoses. These campaigns should aim to reduce stigma and promote a more compassionate approach to those affected by OUD.

Regulatory bodies must enhance surveillance, stricter import controls and more rigorous monitoring of chemical precursors. Healthcare systems need to be equipped with the latest in treatment and overdose-reversal technologies, such as advanced formulations of naloxone, to respond effectively to the unique challenges posed by these potent drugs.

Furthermore, research into the effects and treatments of synthetic opioid exposure must be a priority to stay ahead of these substances as they develop. Only through a comprehensive and informed approach can we hope to mitigate the profound impact of these drugs on individuals, families, and communities.

In conclusion, as we face this new wave of synthetic opioids, our response must be robust, adaptive, and grounded in a deep understanding of the science and sociology of addiction. The stakes are high, and our actions now will shape the health outcomes of generations to come.

Find More

1. First aid for Opioid Overdose
2. Drug Facts Sheet: Synthetic Opiods
3. New Synthetic Opioids: Clinical Considerations and Dangers
4. Overdose Epidemic Report 2023

The post Synthetic Opioids: Crisis 2.0 appeared first on Mindheal.

Naloxone, also known by its brand name Narcan among others, is an opioid antagonist. This means it binds to opioid receptors in the brain but, unlike opioid agonists (like morphine, heroin, or fentanyl), it does not activate these receptors. Instead, it blocks and reverses the effects of other opioids. This action is crucial in counteracting life-threatening depression of the central nervous system and respiratory system caused by opioid overdose.

Main Purposes of Using Naloxone

Opioid Overdose Reversal: Naloxone is most commonly used to counteract life-threatening depression of the central nervous system and respiratory system caused by opioid overdose. This includes overdoses from prescription opioids (like oxycodone or morphine), heroin, and synthetic opioids (like fentanyl).

Harm Reduction Programs: Individuals who use opioids or their family members are given naloxone kits. They are trained to use naloxone in case of an overdose, providing a crucial window for emergency services to arrive. Given its importance in treating opioid overdoses, naloxone is often made available to emergency responders, harm reduction sites, and, in some regions, over the counter to the general public.

Diagnostic Tool: In a hospital setting, naloxone can be used diagnostically to determine whether a person’s symptoms (such as unconsciousness) are due to an overdose of opioids.

Postoperative Care: A patient recovering from surgery has been given opioid painkillers and shows signs of respiratory depression. Naloxone may be administered to counteract the effects of opioids, ensuring safe recovery.

Chronic Pain Management: Patients on high doses of opioids for chronic pain management may have naloxone on hand as a precaution. In case of accidental overdose due to medication error or sensitivity, naloxone can be used for immediate reversal.

History of Naloxone

Naloxone has an interesting history marked by critical milestones in its development and implementation.

Early Development

Naloxone was first synthesized in 1961 by Mozes J. Lewenstein and Jack Fishman, two researchers at the company Sankyo in Japan. Their work was part of a broader effort to create opioid antagonists.

The patent for naloxone was acquired by Endo Laboratories, a small pharmaceutical company in New York. Initial studies focused on its potential to reverse opioid overdose.

FDA Approval and Early Use

Naloxone was approved by the U.S. Food and Drug Administration (FDA) in 1971 for the treatment of opioid overdose. Initially, naloxone was primarily used in medical settings, especially emergency rooms, to treat acute opioid overdose. It was administered intravenously by healthcare professionals.

Expansion of Use and Public Access

With the escalation of the opioid crisis in the 1990s and 2000s, largely fueled by the widespread prescription of opioid pain relievers and the subsequent rise in heroin use, naloxone’s importance grew.

Naloxone became a cornerstone of harm reduction strategies. Programs began distributing naloxone to people who use opioids, as well as their friends and families, to use in emergencies.

Laws and regulations in many areas were amended to increase access to naloxone. These changes often included Good Samaritan laws to protect those administering naloxone in an emergency.

Innovations in Administration

In 2015, the FDA approved a nasal spray version of naloxone, making it easier for non-medical personnel to administer.

Auto-injectors, similar to epinephrine pens for allergic reactions, were also developed, providing another user-friendly option for naloxone administration.

Recent Developments

Naloxone has become increasingly available over-the-counter in many places, and it’s regularly carried by first responders, including police and emergency medical technicians.

There have been significant efforts in public health campaigns to raise awareness about opioid overdose and the availability of naloxone, including training on its use.

Research continues into improving naloxone formulations and delivery methods, as well as integrating its use into broader strategies for addressing the opioid crisis.

Chemical Structure of Naloxone

Naloxone’s molecular formula is C19H21NO4. It features a morphinan skeleton, which is common in many opioid compounds. This structure comprises a fused ring system, including a benzene ring (aromatic ring), a cyclohexene ring, and two cyclohexane rings.

An allyl group (CH2=CH-CH2-) is attached to the nitrogen atom. This is crucial for its antagonist properties.

A ketone group (C=O) is located on the cyclohexenone ring.

An alcohol group (hydroxyl, -OH) on the cyclohexane ring.

An ether linkage (–O–) connects the phenolic ring to the rest of the structure.

Naloxone has several chiral centers, which means it can exist in various stereoisomeric forms. However, the clinically used naloxone is a specific isomer.

Comparison with Similar Compounds

Naltrexone shares a very similar structure to naloxone, with the primary difference being the substitution of the allyl group on naloxone with a cyclopropylmethyl group in naltrexone. This slight modification gives naltrexone a longer duration of action and makes it suitable for the treatment of alcohol and opioid dependence in a longer-term setting, as opposed to the emergency treatment of overdose.

Morphine, an opioid agonist, also shares the morphinan skeleton. Morphine has different functional groups, including two hydroxyl groups and a methyl ether, which contribute to its opioid agonist properties, as opposed to naloxone’s antagonist properties.

Fentanyl, a potent synthetic opioid agonist, does not share the morphinan structure but does interact with the same opioid receptors. Fentanyl’s structure is based on a phenethylamine core, which is significantly different from naloxone’s morphinan base.

Naloxone’s chemical structure is specifically tailored to bind to opioid receptors without activating them, thereby reversing the effects of opioid agonists. Its structural similarity to other opioid-related compounds, like naltrexone, is what allows it to effectively compete with and displace these agonists at the receptor sites. This precise molecular design underlines its effectiveness as an opioid antagonist, crucial in the management of opioid overdose.

Mechanism of Action of Naloxone

Naloxone’s mechanism of action is centered on its interaction with the opioid receptors in the central nervous system (CNS). This interaction is key to its ability to reverse the effects of opioids, particularly in overdose situations. Let’s delve into the details:

Binding to Opioid Receptors

Competitive Antagonism: Naloxone functions as a competitive antagonist at opioid receptors, with the highest affinity for mu-opioid receptors, which are predominantly responsible for the effects of opioids like analgesia (pain relief) and respiratory depression.

Displacement of Opioids: It competes with and displaces opioid agonists (substances that activate receptors) at these receptor sites. Due to its strong affinity, naloxone can effectively dislodge opioids even at low doses, reversing their effects.

Receptor Activity and Effects

Blocking Receptor Activation: Upon binding to the opioid receptors, naloxone prevents the activation of these receptors by opioid agonists. It doesn’t elicit any intrinsic activity at the receptor, meaning it doesn’t activate the receptor’s typical response.

Reversal of CNS and Respiratory Depression: By blocking opioid receptor activity, naloxone reverses central nervous system and respiratory depression – the most life-threatening aspects of opioid overdose. This action restores normal respiratory function and consciousness in individuals experiencing an overdose.

Rapid Onset and Duration of Action

Quick Action: Naloxone acts quickly, typically showing effects within minutes of administration. This rapid onset is crucial in acute overdose situations where immediate reversal of respiratory depression is necessary.

Short Duration: It is a short-acting antagonist. Its effects generally last for about 30 to 90 minutes, depending on factors like the mode of administration and individual metabolism. This duration is often shorter than that of many opioids, necessitating careful monitoring and potentially repeated dosing in an overdose situation.

Impact on Different Opioid Receptors

Mu-Opioid Receptors: As mentioned, naloxone has the highest affinity for mu-opioid receptors. These receptors are primarily implicated in opioid-induced respiratory depression, analgesia, and euphoria.

Kappa and Delta Receptors: Naloxone also binds to kappa and delta opioid receptors, but its clinical effects are predominantly due to its action on mu receptors.

Non-Selective Antagonism: Naloxone’s non-selective antagonism across different opioid receptors makes it effective against overdoses from a broad spectrum of opioids.

Safety Profile: It’s considered a safe medication, even at high doses, with few side effects if given to a person who has not taken opioids.

Naloxone’s Duration of Action

Duration particularly relevant in the context of opioid overdose treatment, is influenced by several factors. Understanding these factors is crucial for effective clinical application.

• Typical Duration: Naloxone’s effects typically last between 30 minutes to an hour, though this can vary. It’s a relatively short-acting drug.
• Half-Life: The half-life of naloxone, which is the time it takes for half of the drug to be metabolized and eliminated from the body, is about 1 to 1.5 hours.

Factors Influencing Duration of Action

1. Mode of Administration and Dosage

• Intravenous (IV): When administered intravenously, naloxone acts almost immediately but also has the shortest duration of action.
• Intramuscular (IM) or Subcutaneous (SC): These routes lead to a slightly slower onset but a longer duration of action.
• Intranasal (IN): This method is comparable to IM or SC in terms of onset and duration.
• Higher doses may have a longer duration of action, but this can vary based on individual metabolism and other factors.

2. Metabolism and Individual Factors:

• Liver Function: Naloxone is metabolized in the liver. Impaired liver function can slow its metabolism, potentially extending its duration of action.
• Renal Function: Since naloxone and its metabolites are excreted primarily by the kidneys, renal impairment might also affect its duration.
• Age, Body Weight, and Genetics: These can all affect how naloxone is metabolized and thus its duration of action.
• Concurrent Drug Use: The presence of other substances, especially other opioids or medications that affect liver enzymes, can influence how long naloxone works.

3. The Potency and Amount of Opioid Overdosed On: In cases of overdose with potent opioids like fentanyl, naloxone’s effect might be shorter than the duration of action of the opioid, necessitating repeated dosing.

Dosages, Routes, and Rules for Naloxone Use

Dosing

• The typical initial dose of naloxone for adults and children is 0.4 to 2 mg.
• This dosage can be repeated every 2 to 3 minutes if the desired response (restored breathing, consciousness) is not achieved.
• The total dose varies depending on the severity of the opioid overdose and the individual’s response.

High-Potency Opioid Overdose: Overdoses involving potent opioids like fentanyl may require higher initial doses, potentially in the range of 2 to 4 mg due to the stronger binding of these opioids to receptors.

Dosage Adjustments: Dosage may be adjusted based on factors like age, body weight, the opioid involved, and the individual’s health status.

Routes of Administration

Intravenous (IV):

• Fastest onset of action, typically within 1-2 minutes.
• Requires medical expertise for administration.
• Often used in hospital settings.

Intramuscular (IM) or Subcutaneous (SC):

• Easier to administer than IV, suitable for emergency responders and in community settings.
• Onset of action is usually within 3-5 minutes.
• Commonly used in pre-filled syringes or auto-injectors (e.g., Evzio).

Intranasal (IN):

• Nasal spray forms (e.g., Narcan, Nyxoid) offer ease of use without the need for injection.
• Onset is slightly slower than IM/IV but still rapid, typically within 3-5 minutes.
• Ideal for bystander administration in emergencies.

Rules of Use

Assessment Before Administration: Confirm signs of opioid overdose: unresponsiveness, shallow or absent breathing, and pinpoint pupils.

Ensure emergency medical services (EMS) are called as naloxone is not a substitute for medical care.

Post-Administration Monitoring: Monitor the individual’s breathing and consciousness after administration.

Be prepared to administer additional doses if the person doesn’t respond or if symptoms return, as naloxone’s duration of action can be shorter than that of the opioid.

Rescue Breathing/CPR: If trained, provide rescue breathing or CPR as needed while waiting for naloxone to take effect or if naloxone is not immediately effective.

Care After Reversal: Once the individual regains consciousness, keep them calm and in a recovery position. Opioid withdrawal symptoms may occur, which can be uncomfortable but are not life-threatening.

Handling Re-narcotization: Due to the short duration of naloxone, watch for signs of re-narcotization as the effect of the opioids may outlast that of naloxone. Have additional naloxone doses available and be ready to administer if symptoms of overdose return.

Use in Special Populations: In pregnant women, naloxone should be used if needed, as opioid withdrawal can be risky for the fetus. Adjust doses cautiously in elderly or patients with underlying health conditions.

Naloxone Limitations

Temporary Measure: It’s important to note that naloxone is a temporary treatment for overdose. Medical care is still needed as the effects can wear off before the opioids in the system.

Potency Concerns: In the context of extremely potent opioids like fentanyl, higher or multiple doses of naloxone may be necessary to be effective.

Ethical and Social Considerations:

• Stigma and Access: There’s an ongoing discussion about the accessibility of naloxone and the stigma surrounding its use, particularly in communities heavily impacted by opioid addiction.
• Empowerment and Responsibility: Making naloxone widely available empowers communities and individuals to act in life-threatening situations, but it also raises questions about responsibility and training for proper administration.

Naloxone Naming

Naloxone is known by various names and trademarks, reflecting its widespread use and manufacturing by different pharmaceutical companies. Here’s a list of alternative names and trademarks for Naloxone:

1. Narcan: This is perhaps the most widely recognized brand name for naloxone. Narcan is commonly used in the context of emergency treatment for opioid overdose and is available in various forms, including nasal spray and injectable solutions.
2. Evzio: This is another brand name for naloxone, known primarily for its auto-injector form. Evzio is designed for rapid and easy administration, making it user-friendly for individuals without medical training.
3. Kloxxado: A relatively newer brand, Kloxxado offers naloxone in a nasal spray form, similar to Narcan, but with a higher concentration of the drug.
4. Nyxoid: This is another nasal spray form of naloxone, available in some regions. Like Narcan and Kloxxado, Nyxoid is designed for ease of use in emergencies.
5. Generic Naloxone: In addition to these brand names, naloxone is also available as a generic medication. Generic naloxone is typically less expensive and is available in various forms, including injectable solutions.

Each of these names or brands represents naloxone but may differ in terms of concentration, formulation, or mode of delivery. These variations are designed to increase accessibility and ease of use, especially in emergencies where rapid response is crucial. The development of different brands and forms of naloxone reflects the increasing recognition of its importance in responding to the opioid crisis.

Final Thought

Naloxone stands as a pivotal tool in modern medicine, particularly in the context of the ongoing opioid crisis. Its ability to rapidly reverse the life-threatening effects of opioid overdose has made it an essential component of emergency medical response and harm reduction strategies. The significance of naloxone in saving lives and mitigating the impact of opioid misuse and overdose cannot be overstated.

The importance of naloxone is twofold: Firstly, it serves as a critical emergency intervention, acting quickly to restore normal breathing in individuals experiencing an opioid overdose. This immediate action reduces the risk of fatal respiratory depression, providing a crucial window for medical intervention. Secondly, naloxone’s accessibility and ease of use have empowered not just healthcare professionals but also laypersons, including people who use opioids, their families, and community members, to act effectively in overdose situations.

However, the full potential of naloxone can only be realized through comprehensive education and training. This includes educating healthcare providers on the appropriate use and administration of naloxone, training community members and first responders in recognizing signs of opioid overdose and administering naloxone, and raising public awareness about the availability and role of naloxone in overdose prevention. Such education is vital in destigmatizing opioid use and overdose, encouraging prompt and effective response, and ultimately saving lives.

Sources for More

1. Naloxone Effectiveness: A Systematic Review

2. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States

3. Pharmacists’ naloxone services beyond community pharmacy settings: A systematic review

The post Naloxone Explaining appeared first on Mindheal.

Wooden Chest Syndrome (WCS) refers to the stiffening of the chest observed after administration of a high dose of opioids during anesthesia or recreationally. Wooden Chest Syndrome is a rare but potentially life-threatening complication that can occur in patients who have a history of chronic opioid use.

This phenomenon is characterized by pronounced muscle stiffness, predominantly in the thoracic and abdominal regions. This rigidity can complicate the ventilation process. It’s an infrequent side effect linked to the IV administration of lipophilic synthetic opioids like fentanyl.

There is an opinion that WCS could play a role in certain fatalities associated with the intravenouse (IV) use of fentanyl, which is now more commonly found in heroin samples. Therefore, it seems important to me to talk about this syndrome.

Mechanisms of Fentanyl Chest Wall Rigidity

Wooden Chest Syndrome, also known as Fentanyl Induced Chest Wall Rigidity was initially documented in 1953. Over the years, there has been a growing number of global case studies highlighting this condition.

The exact mechanism of WCS remain somewhat elusive, but it appears to be driven centrally and is not a result of suppressed respiratory system directly. Some experts suggest that the coerulospinal noradrenergic route might play a role through α-1 adrenoreceptors located in the spinal cord. Meanwhile, there are theories pointing towards the involvement of the dopaminergic system.

The following idea of the WCS mechanism seems to me to be the most complete to date. Extended contraction of the chest wall muscles is due to the binding of opionds to µ-opioid receptors (MOR) in the central nervous system. The agonism by fentanyl and its analogs at MOR in the brainstem’s locus coeruleus (LC) seems to activate the α-adrenoceptors of the LC and spinal cord, increasing the noradrenergic outflow from the LC. At the same time the stimulation of a dopaminergic route happens. This leads to reduced flexibility in the chest wall, causing challenges in both assisted and spontaneous breathing. This, in turn, results in increased pressures within the ventilation system.

Risk Factors for Fentanyl Rigid Chest

The specific risk factors for developing Wooden Chest Syndrome are not extensively documented in the literature. Based on the available data, here are some potential risk factors:

• High cumulative doses of fentanyl (10-15 microgrames per kilo): The syndrome is particularly associated with the use of fentanyl, especially at high doses.
• Lipophilic synthetic opioids: Fentanyl, remifentanil, sufentanil, etc.
• Rapid IV administration: Rapid administration or bolus doses of opiods might increase the risk.
• Concomitant use of meds that modify dopamine levels: This may increase the risks, but needs additional evidence.
• Concurrent Medical Conditions: Patients with underlying respiratory conditions or those who are critically ill, such as those with acute respiratory distress syndrome (ARDS), might be more susceptible to the effects of fentanyl on respiratory muscles.
• Sedation Level: Deep sedation using agents like fentanyl and midazolam might predispose patients to develop Wooden Chest Syndrome.
• Individual Susceptibility: Some individuals might be more susceptible to the effects of opioids due to genetic or metabolic reasons.
• Extremes of age.

It’s essential to note that while these factors might increase the risk, the exact cause and predisposing factors for Wooden Chest Syndrome are not entirely understood. Clinicians should be vigilant when administering fentanyl, especially in high doses or in patients with potential risk factors.

Role of Fentanyl and its Analogs

While the high potency and low cost of fentanyl and its analogs (F/FAs) contribute to their widespread distribution, their basic pharmacology differs fundamentally from conventional opioids like morphine and heroin. This question is perfectly disclosed in the article Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose

F/FAs, in addition to causing respiratory depression through opioid receptors, also induce rigidity in key respiratory muscles, leading to the fentanyl chest wall rigidity via a non-opioid mechanism.

Fentanyl and its analogs have a unique characteristic not shared by opioids like morphine and heroin. Fentanyl is a synthetic opioid agonist with a binding affinity at the μ-opioid receptor. It has a rapid onset of action and higher analgesic potency than morphine. F/FAs were significant for surgical anesthesia due to their rapid action, high potency, and hemodynamic stability.

But they are common in street drugs primarily for economic reasons. F/FAs are synthetically produced, eliminating the need for poppy cultivation. While a kilogram of heroin might cost $65,000, the same amount of F/FA costs about $3,500.

Today wooden chest syndrome is well-known to anesthesiologists but not among recreational drug users. This lack of awareness increases the danger, especially since WCS is more likely with rapid injection and high doses.

Both known and unknown uses of F/FAs are on the rise. Some recreational drug users prefer F/FAs over other drugs, and fentanyl and co that were once secretly added to the drug supply are now a selling point for street drugs.

Signs and Complications of Rigid Chest Syndrome

WCP is characterized by a patient’s inability to properly ventilate due to the rigidity of the chest wall. It manifests as heightened muscle tension in the chest and abdominal areas, uneven breathing patterns, laryngospasm, diaphragm rigidity, elevated carbon dioxide levels, and sigs of acute respiratory distress.

This reaction can be seen both in sustained fentanyl infusions and in sudden doses, like those administered for pain management during procedures or in recreational purposes.

Physical examination might reveal a tense abdomen, facial cyanosis (bluish discoloration due to lack of oxygen), and episodes that appear to be breath-holding spells.

People breathing on their own might show signs of high blood pressure, decreased oxygen levels, and muscular tension after receiving a fentanyl bolus.

For those who are intubated and on fentanyl drips, sudden spikes in airway pressures and episodes of breath retention are primary indicators. It’s essential to think of chest wall stiffness after ensuring there’s no upper airway blockage or bronchial spasms.

Other diagnostic tools, such as bronchoscopy and chest X-ray, usually do not show any obstruction or other abnormalities.

Potential complications of the fentanyl rigid chest include low oxygen levels, elevated blood pressure, increased pulmonary pressure, respiratory acidosis, rise in intracranial pressure and potential respiratory collapse.

Recommendations and Treatment for WCS

1. Immediate Recognition: If a person on fentanyl starts showing signs of respiratory distress, clinicians should consider the possibility of Wooden Chest Syndrome.
2. Reduce or Stop Fentanyl: If suspected, the fentanyl infusion should be reduced or stopped.
3. Alternative Sedation: Transitioning the person to alternative sedative agents, such as dexmedetomidine, can be considered.
4. Supportive Care: Ensure the pesron has adequate oxygenation and consider manual ventilation if required.

The approach to treatment is contingent on the patient’s breathing status.

• For those breathing independently, simply stopping the opioid (optionally combined with naloxone reversal) and providing supportive breathing assistance suffices.
• For patients on mechanical ventilation, the recommended treatment encompasses:
  • Halting the opioid (avoiding naloxone is advised; reversing pain relief in an intubated patient should be a last resort).
  • Substituting the opioid with a non-lipophilic alternative (like hydromorphone or morphine) for pain relief.
  • Introducing a non-depolarizing agent for muscle paralysis.
  • Offering supportive breathing assistance.

There’s also a variation in case studies about the choice and duration of neuromuscular blockers. Evidence supports the effectiveness of non-depolarizing agents like vecuronium and cisatracurium. Most cases involved a continuous paralytic infusion lasting 24-48 hours.

Naloxone in Wooden Chest Syndrome

Naloxone, an opioid receptor antagonist, is effective in reducing opioid-associated respiratory depression. However, it’s less beneficial in reversing potentially fatal laryngospasm or respiratory muscle rigidity caused by fentanyl and its analogs. Moreover, naloxone’s short half-life can sometimes be problematic in opioid rigid chest syndrome rescue.

It is important to be cautious when administering opioid antagonists because they can cause a sudden reversal of the effects of opioids, which can lead to withdrawal symptoms and other adverse effects. In some cases, the use of opioid antagonists can also trigger Wooden Chest Syndrome, as the authors of the article Wooden chest syndrome: Beware of opioid antagonists, not just agonists note.

There’s a range of opinions in case studies about the best approach. Some found success just by stopping the opioid, while others incorporated naloxone. However, naloxone should be administered judiciously and reserved for intubated patients when other strategies don’t work.

If someone is suspected of having Wooden Chest Syndrome or any opioid-related complication, it’s crucial to seek medical attention immediately. Opioids can have various side effects, and their use should be closely monitored by healthcare professionals.

Case Report

A 61-year-old female with a history of pancreatitis developed acute respiratory distress syndrome (ARDS) and required intubation. She was sedated with fentanyl and midazolam. After increasing the fentanyl dose, she began experiencing periods of hypoxia. The clinical presentation raised concerns for Wooden Chest Syndrome. The fentanyl infusion was reduced, and she was transitioned to dexmedetomidine.

The authors of the article Wooden Chest Syndrome: A Case Report… note:

Management of this syndrome is with the opioid receptor antagonist Naloxone, neuromuscular blocking agents such as rocuronium, or cessation of fentanyl infusion with supportive care. In light of the coronavirus disease 2019 pandemic and surge in intensive care unit admissions, analgesic fentanyl use has risen. Therefore, an understanding of this complication is necessary.

Final Tought

Today Wooden Chest Syndrome, a rare but serious complication primarily associated with the opioid fentanyl, serves as a stark reminder of the potential dangers of opioid use, both in medical settings and recreationally.

The increasing prevalence of fentanyl and its analogs in illegal drug markets heightens the risk for unsuspecting users. This underscores the importance of public awareness, education, and the need for healthcare professionals to be vigilant when administering opioids.

While the exact mechanisms and risk factors for WCS are still being explored, the condition emphasizes the broader challenges in managing the opioid crisis. It’s a testament to the delicate balance required in pain management—providing relief while ensuring patient safety.

As we continue to grapple with the complexities of opioid use and misuse, WCS stands as a poignant example of why ongoing research, education, and caution are paramount.

The post Opiates Wooden Chest Syndrome appeared first on Mindheal.

An opioid overdose occurs when an individual takes an excessive amount of opioids, such as prescription painkillers (e.g., oxycodone, hydrocodone) or illicit substances like heroin or fentanyl. Opioids are potent pain-relieving medications that affect the central nervous system.

Why can an opioid overdose cause death? So, when opioids are taken in high doses, they can depress the respiratory center in the brainstem, which controls breathing. This leads to a decrease in the rate and depth of breathing, and in severe cases, it can cause respiratory arrest, where breathing completely stops. As a result, oxygen supply to the body decreases, and carbon dioxide levels rise, leading to a cascade of harmful effects.

Risk factors for opioid overdose

Several risk factors can contribute to an increased likelihood of opioid overdose. It is important to be aware of these factors to identify individuals who may be at higher risk and take appropriate preventive measures. Here are some key risk factors:

High-dose or long-term opioid use

Taking higher doses of opioids or using them for an extended period increases the risk of developing tolerance and strong addictive behavior, which can lead to accidental overdose.

Tolerance refers to the body’s ability to process a specific drug. A person with low tolerance requires a smaller amount of a drug to experience its effects, while someone with increased tolerance needs higher doses.

Tolerance develops over time, meaning long-term users require larger amounts of a drug to achieve the desired effects compared to newer users. Tolerance can fluctuate based on factors such as weight, size, illness, stress, compromised immune system, and age.

Notably, tolerance can decrease rapidly after a period of abstinence, whether intentional (e.g., during drug treatment or methadone detox) or unintentional (e.g., due to incarceration or hospitalization). Research also suggests that tolerance is affected when drugs are used in a new or unfamiliar environment, putting individuals at a higher risk of overdose.

Concurrent use of multiple substances

When different drugs are taken together, they can interact in ways that amplify their overall effects. Many overdoses occur when heroin or prescription opioids, alcohol, and benzodiazepines like Klonopin, Valium, and Xanax are mixed. The majority of fatal overdoses result from using multiple drugs simultaneously.

Sedating medications individually carries overdose risks. However, when combined, the risk is significantly increased because these drugs affect the body’s sedation mechanisms in different ways. These mechanisms provide overlapping protection for the brain and respiration. Combining multiple substances diminishes this overlapping protection, meaning that even a smaller amount of heroin can cause an overdose when there are higher levels of alcohol and/or downers present in the system.

Speedballing, which involves mixing heroin and cocaine, is another common drug combination. Despite the assumption that the stimulant and depressant effects would counterbalance each other, the risk of overdose remains high for speedball users. This is likely due to factors such as increased drug processing by the body, the stimulant’s effect on oxygen usage, the depressant’s impact on breathing rate, and the frequency of injection among speedball users.

Previous overdose

A history of prior opioid overdose is a significant risk factor for future overdoses. Surviving an overdose does not guarantee immunity from future incidents, and subsequent episodes may be even more dangerous.

Lack of familiarity with opioids

Individuals who are not familiar with opioid medications, their potency, or safe use practices may be at higher risk of unintentional overdose. This includes individuals who may come into contact with opioids through prescription use, sharing medications, or using illicit drugs.

Opioid potency and source

The use of illicitly manufactured opioids, particularly fentanyl and its analogs, has contributed to a significant increase in overdose deaths. These potent synthetic opioids may be mixed with other drugs, making it challenging for individuals to know the exact contents and dose, thereby increasing the risk of overdose.

The term “quality” refers to the purity and strength of a drug. Street drugs are often unpredictable in terms of content and purity. They may be adulterated with other substances that pose additional dangers. Assessing the purity of drugs visually is not possible, and purity levels can vary, resulting in unexpectedly strong doses that increase the risk of overdose.

Prescription drugs also pose risks. While the contents and dosages of pills are known, the strength can still differ between different types of medications within the same opioid family (e.g., OxyContin vs. Vicodin). Understanding the strength and dosage of both street drugs and prescription medications is crucial for avoiding overdose.

Mental health conditions

Co-occurring mental health disorders, such as depression, anxiety, or post-traumatic stress disorder (PTSD), can increase the risk of opioid overdose. These conditions may lead to self-medication with opioids, resulting in higher doses or misuse.

Age and gender

Certain age groups and genders may be at higher risk. Middle-aged adults (25-54 years old) have shown higher rates of opioid overdose deaths compared to other age groups. Men have historically had higher rates of opioid overdose, although recent years have seen an increase in overdose rates among women as well.

Age and physical health significantly influence the body’s ability to handle drugs. Older individuals and those with prolonged histories of drug use are at higher risk of fatal overdose. While experience with substances can be somewhat protective, long-term substance use, coupled with conditions like viral hepatitis, HIV/AIDS, or infections such as endocarditis or cellulitis, can reduce resilience. Older individuals who overdose are less likely to survive compared to younger individuals. Compromised immune systems, recent illnesses, or weakened states increase the risk of overdose. Dehydration, lack of eating or sleeping also elevate the risk.

Stimulant users with additional health issues like high blood pressure, heart disease, diabetes, high cholesterol, or smoking are at higher risk of experiencing seizures, strokes, or heart attacks.

A recent release from incarceration

Individuals who have recently been released from correctional facilities face an increased risk of overdose due to factors such as a reduced tolerance to opioids, difficulty accessing treatment and support services, and exposure to high-risk environments.

Social isolation and stigma

Social isolation, lack of support networks, and the presence of Stigma surrounding opioid use can contribute to increased risk. These factors may deter individuals from seeking help, limit access to resources, and increase the likelihood of using opioids in unsafe or unsupervised environments.

While using drugs alone does not directly cause overdose, it significantly increases the likelihood of a fatal overdose. If an overdose occurs when someone is alone, there is no one present to call for help or provide immediate assistance. Many fatal overdoses have been discovered in closed or locked spaces, preventing intervention.

It is important to note that having one or more risk factors does not mean an individual will experience an overdose. However, recognizing these factors can help identify individuals who may benefit from targeted interventions, such as education, harm reduction strategies, and appropriate treatment options for substance use disorder.

Symptoms & Signs of opioid overdose

Opioid overdose symptoms can vary, but some common indicators include:

1. Slow or shallow breathing: Opioids can depress the respiratory system, causing breathing to become slow, irregular, or even stop altogether.
2. Extreme drowsiness or unresponsiveness: Opioid overdose can lead to severe sedation, making it difficult for the affected person to stay awake or respond to stimuli.
3. Pinpoint pupils: One characteristic sign of opioid overdose is constricted or pinpoint pupils, where the black center of the eye appears very small.
4. Pale or clammy skin: Due to decreased blood flow, the skin may become pale, cool, and sweaty to the touch.
5. Bluish lips or nails: Lack of oxygen can result in a bluish or purplish discoloration of the lips, face, or nail beds.
6. Slow heart rate: Opioids can lower heart rate, leading to bradycardia, where the pulse is unusually slow.

If you suspect someone is experiencing an opioid overdose, it is crucial to seek immediate medical help by calling emergency services.

Emergency Responses to Opioid Overdose

When responding to an opioid overdose, it is crucial to take immediate action. Here are the recommended emergency responses and treatments for opioid overdose:

1. Call emergency services: Dial the emergency number in your country (such as 911 in the United States) to request immediate medical assistance. Provide clear and accurate information about the situation, including the possibility of an opioid overdose.
2. Stay with the person: Do not leave the individual alone, as their condition can deteriorate rapidly. Stay by their side to monitor their vital signs and provide reassurance until medical help arrives.
3. Administer naloxone if available: If you have access to naloxone, follow the instructions provided with the medication and administer it promptly. Naloxone is available as an injectable medication or as a nasal spray. It can reverse the effects of opioid overdose by blocking the opioid receptors in the brain, restoring normal breathing and consciousness.
4. Support their breathing: Ensure that the person’s airway is clear and open. If they are not breathing or have shallow breathing, perform rescue breaths by giving mouth-to-mouth resuscitation. If you are trained in cardiopulmonary resuscitation (CPR), you may also initiate chest compressions if needed.
5. Stay on the line with emergency services: If you called emergency services, remain on the line to provide any necessary updates or receive further instructions from the dispatcher. They may be able to provide guidance on how to perform CPR or other life-saving measures if needed.

Remember, time is critical during an opioid overdose. By promptly seeking professional medical help and administering naloxone if available, you can significantly improve the chances of a positive outcome.

Learn more about First Aid for Opioid Overdose

Prevention of opioid overdose

Preventing opioid overdose involves various strategies aimed at reducing the risk of overdose and promoting safer opioid use. Here are some key preventive measures:

Education and awareness: Public education campaigns play a vital role in raising awareness about the risks associated with opioid use and overdose. Educating individuals about the signs of opioid overdose, proper medication use, and the importance of seeking help for substance use disorders can help prevent overdoses.

Prescription guidelines and monitoring: Healthcare providers should follow evidence-based guidelines when prescribing opioids, including assessing the patient’s risk for substance misuse, using the lowest effective dose, and considering non-opioid alternatives for pain management whenever possible. Regular monitoring and communication with patients can help identify any misuse or signs of dependence.

Naloxone availability and training: Naloxone is a life-saving medication that can rapidly reverse opioid overdose. Expanding access to naloxone and providing training on its administration to healthcare professionals, first responders, individuals at risk of overdose, and their family members can significantly reduce overdose deaths.

Medication-assisted treatment (MAT): MAT combines medications like methadone, buprenorphine, or naltrexone with counseling and behavioral therapies. It is an evidence-based approach for treating opioid use disorders, reducing cravings, and decreasing the risk of overdose. Expanding access to MAT and reducing barriers to treatment are critical in preventing overdoses.

Harm reduction strategies: Harm reduction approaches aim to minimize the negative consequences of drug use without necessarily requiring abstinence. Examples include needle exchange programs, safe injection sites, and providing information on safer drug use practices. These strategies can help reduce the risk of overdose and the transmission of infectious diseases.

Support and treatment services: Ensuring that individuals have access to comprehensive support and treatment services for substance use disorders is crucial. This includes counseling, therapy, support groups, and rehabilitation programs tailored to meet the specific needs of individuals struggling with opioid use.

Responsible medication disposal: Proper disposal of unused or expired medications can help prevent accidental or intentional misuse. Follow local guidelines or participate in drug take-back programs to ensure safe disposal of opioids.

Prevention of opioid overdose requires a multifaceted approach involving education, policy changes, access to treatment, and support services. By implementing these strategies, we can work towards reducing the incidence of opioid overdose and promoting safer opioid use practices.

Statistics of opioid overdoses in the United States

Here are some key opioid overdose statistics related in the United States according to the Centers for Disease Control and Prevention (CDC) or the National Institute on Drug Abuse (NIDA).

Opioid overdose deaths: In recent years, the United States has been facing a significant opioid crisis. According to CDC data, in 2019, there were over 49,000 opioid overdose deaths, which accounted for nearly 70% of all drug overdose deaths in the country.

Prescription opioids vs. synthetic opioids: Prescription opioids, such as oxycodone and hydrocodone, were initially major contributors to the opioid crisis. However, in recent years, synthetic opioids, particularly illicitly manufactured fentanyl, have been increasingly involved in overdose deaths. Fentanyl is estimated to be 50-100 times more potent than morphine.

Geographical variation: Opioid overdose rates can vary across different states and regions within the United States. Some areas, particularly in the Midwest and Appalachia, have been heavily affected by the opioid crisis, experiencing higher rates of opioid overdose deaths.

Impact on demographic groups: Opioid overdoses have affected various demographic groups, but certain populations have been disproportionately impacted. Men, individuals aged 25-54, and non-Hispanic White individuals have experienced higher rates of opioid overdose deaths. However, opioid use and overdose affect people from all backgrounds and socioeconomic statuses.

Opioid use disorder prevalence: The number of individuals struggling with opioid use disorder is significant. In 2019, an estimated 10.1 million people aged 12 or older misused opioids in the United States.

Tips and recommendations to prevent opioid overdose

Here are some tips and recommendations regarding the risks of opioid overdose. It is logical that the advice on dosage prevention follows directly from the most common risk factors of opioid overdose. Basically, I borrowed them from the National Harm Reduction Coalition – no one wrote so simply, clearly, and intelligently about this topic as they did.

No Combining Drugs

• Use only one drug at a time or reduce the amount of each drug used.
• Avoid combining alcohol with heroin or pills, as this combination is extremely dangerous.
• If using both alcohol or pills and heroin, consume the heroin first to better gauge the level of intoxication. Alcohol and benzos impair judgment, making it harder to remember or be aware of the amount consumed.
• Have a trusted friend present who is aware of the drugs taken and can provide assistance in case of an emergency.

Consider the Tolerance

• Use smaller amounts of a drug when sick or after a period of abstinence, as tolerance may be lower.
• Exercise caution and start with smaller doses when using drugs after a period of abstinence.
• Consider doing a tester shot or gradually increase the dosage.
• Try using a different method, such as snorting instead of injecting.

Remember about Quality

• Test the strength of a drug before consuming the full amount.
• Try to purchase drugs from the same dealer consistently to gain a better understanding of their quality.
• Seek information from others who have obtained drugs from the same dealer.
• Familiarize yourself with the pills you are taking.
• Exercise caution when switching from one type of opioid pill to another.

No Using Alone

• Whenever possible, use drugs with a trusted friend present.
• Develop an overdose plan with friends or partners.
• Keep the door unlocked or slightly ajar for easier access in case of an emergency.
• Inform someone you trust about your drug use and request periodic check-ins.
• Some individuals may have a sense of when they are about to overdose. If you possess this ability, consider having naloxone (a medication used to reverse opioid overdoses) readily available. There have been cases where people have self-administered naloxone.

Take Care of Your Health

• Stay hydrated and maintain a balanced diet.
• If you have liver damage, avoid pharmaceuticals with high levels of acetaminophen, such as Vicodin and Percocet.
• Carry your inhaler if you have asthma and inform your friends about its location in case of breathing difficulties.
• Exercise caution when using drugs after a period of sickness, weight loss, or feeling weak, as it can impact your tolerance.
• Consult with a nonjudgmental doctor to assess other health factors that may increase your risk of stimulant overdose, such as high blood pressure, high cholesterol, heart disease, or other physical conditions that may raise the risk of a stroke or heart attack.

Other tips

• Follow the prescribed dosage and instructions.
• Seek medical advice before stopping or changing medication.
• Store opioids safely: Keep opioids securely stored in a locked cabinet or container to prevent accidental ingestion by children, adolescents, or visitors. Proper storage reduces the risk of unauthorized use or accidental overdose.
• Dispose of unused opioids properly: When you no longer need your opioid medication or it has expired, follow recommended disposal guidelines. Some communities have drug take-back programs or designated drop-off locations.
• Educate yourself and others: Stay informed about the risks associated with opioid use and overdose. Share this knowledge with friends, family, and community members to raise awareness and help prevent overdose incidents.
• Be prepared to respond to an overdose: Learn about naloxone, an opioid overdose-reversal medication, and how to administer it. Consider having naloxone on hand if you or someone you know is at risk of opioid overdose. Training on CPR and rescue breathing techniques can also be valuable in case of an emergency.

Conclusion

What is an opioid overdose? It’s not just a medical or personal problem. Opioid overdose poses a significant and ongoing risk, contributing to a public health crisis in many countries, including the United States. The situation demands attention and action from individuals, healthcare providers, policymakers, and communities. Understanding the risks associated with opioid use and overdose is crucial in addressing this complex issue. Here are key points to consider:

Opioid overdose deaths: Opioid overdose deaths have been on the rise, with opioids accounting for a substantial portion of all drug overdose deaths. Synthetic opioids, particularly illicitly manufactured fentanyl, have become a major concern.

Prescription practices: Proper prescribing practices, including risk assessment, judicious use of opioids, and considering alternative pain management options, are important for preventing misuse and overdose.

Substance use disorder: Opioid misuse and overdose often indicate an underlying substance use disorder. Providing accessible and comprehensive treatment options, including medication-assisted treatment, counseling, and support services, is critical in addressing the root causes of opioid addiction.

Harm reduction: Implementing harm reduction strategies such as naloxone distribution programs, safe injection sites, and education on safer drug use practices can save lives and reduce the negative consequences associated with opioid use.

Education and awareness: Raising public awareness about the risks of opioid use, signs of overdose, and available resources is crucial in preventing overdoses and promoting safer practices.

Collaboration and policy changes: Combating the opioid crisis requires a collaborative effort involving healthcare providers, policymakers, law enforcement, and community organizations. Implementing evidence-based policies, improving access to treatment, and addressing the social determinants of opioid addiction can help mitigate the crisis.

It is important for individuals to take precautions, such as following prescribed medication instructions, storing opioids safely, and being aware of potential interactions. Proper disposal of unused opioids and being prepared to respond to an overdose with naloxone and appropriate emergency procedures are also essential.

By addressing the risks associated with opioid use, increasing access to treatment, and implementing comprehensive prevention strategies, we can work towards reducing opioid overdose incidents and supporting individuals affected by opioid addiction.

The post Opioid Overdose Risks appeared first on Mindheal.

Opioid withdrawal refers to the physical and psychological symptoms that occur when someone who has been regularly using opioids suddenly stops or reduces their use. The severity of withdrawal symptoms can vary depending on the individual’s level of opioid use and can include:

Symptoms

Those who go through opioid withdrawal often describe it as being similar to the flu and includes heightened sensitivity to pain and tactile stimulation.

• Runny nose, sneezing, and watery eyes: Opioids can constrict blood vessels, including those in the nose and eyes. When opioids are withdrawn, the blood vessels dilate, leading to a runny nose and watery eyes.
• Sweating and chills: Opioids can affect the body’s temperature regulation, and when they are withdrawn, the body may experience sweating and chills.
• Impaired perception of temperature: Sensitivity to cold or heat. Also due to temperature sensitivity dysregulation.
• Muscle and bone pain: Opioids can decrease pain sensitivity, and when they are withdrawn, pain sensitivity returns, leading to muscle fatigue and bone aches.
• Nausea and vomiting: Stomach upset and the urge to vomit. Opioids can slow down the digestive system, and withdrawal can cause it to speed up, leading to nausea and vomiting.
• Abdominal cramps and pain: Physical discomfort or pain in the abdomen. Problems with appetite.
• Diarrhea: Loose or watery stools. Like nausea and vomiting, diarrhea is a result of the digestive system speeding up during withdrawal.
• Yawning: Yawning is a common symptom of opioid withdrawal, possibly because opioids affect the brain’s dopamine system, which is involved in the regulation of yawning.
• Dilated pupils: Enlargement of the pupils. This phenomenon is observed in the late stage of withdrawal.
• Goosebumps and skin crawling.
• Agitation: Feelings of restlessness, or panic.
• Anxiety: Opioids affect the brain’s reward system and produce feelings of pleasure and well-being. When a person stops using opioids, the brain’s reward system is disrupted, and anxiety can result.
• Insomnia: Opioids can cause drowsiness, so when a person stops using them, they may have trouble sleeping.
• Demotivation, anhedonia, depression. Difficulties with getting pleasure, active and purposeful actions, and emotional state. All this is developing in connection with the imbalance of the reward system.
• Cravings. With difficult, but surmountable cravings to the level of obsessive thoughts and compulsive actions aimed at finding, acquiring, and using еру substance.

Opioid receptors become down-regulated in response to repeated usage, causing withdrawal, which is not expected to occur in opioid-naive individuals or those who use episodically. However, unfortunately (or fortunately) there are no clear guidelines suitable for everyone, on how to use opioids and not experience withdrawal syndrome.

Opioids with a shorter half-life, such as heroin, are well-known for inducing withdrawal symptoms intolerant individuals within a few hours of clearing the body. Longer-acting opioids like methadone, on the other hand, will result in withdrawal symptoms much later, but the effects will last longer than those of shorter-acting opioids. Conversely, faster-acting opioids such as fentanyl will exhibit withdrawal symptoms more quickly, but the effects will subside faster than those of longer-acting opioids.

Symptoms of opioids withdrawal typically occur within 3 to 30 hours after the last opioid use and can last for several days or weeks. The length and severity of withdrawal can vary depending on the individual and their level of opioid use.

When using opioids, harm reduction principles can help. Also pay attention to the article about first aid for opioid overdose.

What can be done?

If a person is experiencing opioid withdrawal symptoms at home, there are several methods, actions, medications, and techniques that can help alleviate their symptoms:

Tapering. The intensity of withdrawal symptoms may be mitigated by gradually reducing the dosage of the substance prior to complete cessation. Nevertheless, this approach will prolong the process of discontinuing the drug. Thus, some individuals who have already experienced the manifestation of opioid withdrawal opt for sudden cessation. This approach typically results in a more challenging experience, but with a faster resolution. Nonetheless, tapering off the dosage in a gradual manner may still remain a viable option.

Over-the-counter medications: Some over-the-counter medications, such as ibuprofen, acetaminophen, aspirin, or naproxen, can help alleviate muscle and bone pain as well as flu-like symptoms, associated with opioid withdrawal. With a certain degree of probability, nonsteroidal anti-inflammatory drugs can help with opioid withdrawal.

Staying hydrated: Drinking plenty of fluids can help alleviate symptoms such as nausea, diarrhea, and sweating.

Eating a balanced diet: Eating a balanced diet can help provide the body with the nutrients it needs to cope with withdrawal. It is important to keep in mind that during the initial phase of experiencing issues with appetite and digestion, it may not be feasible to consume food in a regular manner. Therefore, it is advisable to initiate a dietary regimen only after the acute and severe phase of withdrawal has passed.

Exercise and relaxation techniques: Simple and pleasant exercise without a sports component, such as taking a walk, will help alleviate symptoms, improve mood, and recover faster. Techniques such as deep breathing, meditation, or yoga can help alleviate stress and anxiety associated with withdrawal. But also they are not worth it, and it will not work to be used in the severe withdrawal syndrome.

It’s important to note that opioid withdrawal can be challenging, and seeking professional help is often the best course of action. If a person is experiencing severe or prolonged symptoms, they should seek medical attention immediately.

Opioid replacement therapy

This method involves using longer-lasting but less recreational opioids like methadone and buprenorphine to alleviate cravings, ease withdrawal symptoms, and neutralize the euphoric effects of other opioids.

If you’re considering replacement therapy, it’s recommended that you work closely with a physician to gradually decrease your dosage over time rather than suddenly stopping altogether. This can help minimize negative effects and ensure a smoother transition toward sobriety. By following your doctor’s guidance and taking advantage of the benefits of opioid replacement therapy, you can overcome opioid addiction and take back control of your life.

Opioid withdrawal is difficult. Perhaps the most difficult among the withdrawal symptoms due to a combination of physical and psychological manifestations that can make a person’s life unbearable. But it is possible with the right support and resources. Medical detoxification, under the supervision of a doctor or addiction specialist, can help manage withdrawal symptoms and increase the chances of success. If you or someone you know is struggling with opioid addiction, it’s important to seek help from a medical professional for a personalized treatment plan and support.

The post Symptoms of opioids withdrawal appeared first on Mindheal.

Opioids work by binding to specific receptors in the brain and spinal cord, which can reduce the perception of pain and create a feeling of euphoria. However, when too much of an opioid is taken, it can cause the respiratory system to slow down or even stop, leading to a lack of oxygen to the brain and other vital organs. This can cause brain damage or death.

Opioid overdose is particularly dangerous because it can happen quickly and unexpectedly, even in people who have been taking opioids for a long time. Additionally, the potency of illegal opioids like fentanyl is much higher than that of other opioids, which means that a small amount can be fatal.

Recognizing an overdose

It is crucial to note that opioid overdose can occur to anyone, regardless of whether they have a history of opioid use or not. Hence, it is imperative to be cognizant of the signs and symptoms and to take them seriously if they manifest.

Recognizing an opioid overdose can be a formidable task as the indications and manifestations can fluctuate contingent on the opioid and quantity consumed. Nonetheless, some prevalent signs of an opioid overdose include:

• The fact of opioid use known or obvious
• A person is awake but unable to talk.
• Their body is very limp.
• The face is very pale or clammy.
• Fingernails and lips turn blue or purplish black.
• For lighter-skinned people, the skin tone turns bluish-purple, for darker-skinned people, it turns grayish or ashen.
• Breathing is very slow and shallow, erratic, or has stopped.
• Pulse is slow, erratic, or not there at all.
• Choking sounds, or a snore-like gurgling noise.
• Vomiting.
• Loss of consciousness.
• Unresponsive to outside stimuli.

First aid for opioid overdose

I. Stimulation

If the person is unconscious, first attempt to rouse them by calling their name. Additionally, you can employ statements that may elicit a response, such as “I am going to call 911.” Should they remain unresponsive, attempt to stimulate them through mild pain by gently rubbing your knuckles into the sternum, or by squeezing and gently pulling the person’s earlobe. You can also pinch the hand or gently rub the upper lip of a person with your knuckles.

If this causes the person to wake up, try to get them to focus. Continuously monitor them, particularly their breathing and pulse, and attempt to keep them awake and alert. If their breathing is shallow, they mention feeling short of breath, or they are experiencing chest tightness, call 911 immediately.
If the person does not respond to stimulation and remains unconscious or the condition appears to worsen, do not try a different or alternative form of stimulation. Treat this as a medical emergency and call 911 immediately.

II. Recovery Position

If you need to leave the overdosing person at any time – even for a minute to call 911 – ensure that they are placed in the Recovery Position. Read more about this method in the article.

III. Call for Help

It is advisable to call 911 in the event of an overdose as it is crucial to have trained medical professionals evaluate the condition of the overdosing person.

Inform the paramedics of your exact location and the overdosing person’s location, and give as much information as possible to facilitate quick identification.

While communicating with the dispatcher on the phone, avoid using words such as drugs or overdose; stick to observable symptoms such as “The person is not breathing, turning blue, unconscious, non-responsive, etc.” This makes the call a priority, as it will be identified as a life-threatening emergency. The dispatcher does not need to know the details of the situation, only that there is an emergency that requires immediate assistance.

When calling 911, minimize loud noise in the background – if it sounds chaotic, they will dispatch police to secure the scene and protect the paramedics.

When the paramedics arrive, provide them with as much information as possible; inform them of what drugs the person may have been using, when they used them, and whether naloxone was administered, etc. If the paramedics suspect opioid use, they will administer an injection or intranasal dose of naloxone. Remember, the paramedics’ primary goal is to address the health of the individual and respond to the medical emergency.

IV. Perform Rescue Breathing

If someone has extremely shallow and intermittent breathing (around one breath every 5-10 seconds) or has stopped breathing and is unresponsive, rescue breathing should be performed as soon as possible; it is the quickest way of getting oxygen to someone who has stopped breathing.

If you are performing rescue breathing, you are getting much-needed air into someone’s body who will die without it; the difference between survival and death in an opioid overdose depends on how quickly enough oxygen gets into the person’s body.

This video explains in detail and clearly the process of rescue breathing:

It’s not difficult. Here are the main steps and the sequence of actions in the text:

1. Place the person on their back.
2. Tilt their chin up to open the airway.
3. Check to see if there is anything in their mouth blocking their airway—such as gum, or toothpick—and if so, remove it.
4. Pinch their nose with one hand, place your mouth over the overdosing person’s mouth, and give 2 even, regular-sized breaths. Blow enough air into their lungs to make their chest rise. If you don’t see their chest rise out of the corner of your eye, tilt the head back more, make sure you’re plugging their nose, and also make sure you have a good seal over the victim’s mouth.
5. After 5 seconds, breathe again. Give one breath every 5 seconds until the person starts breathing on his or her own or until emergency responders arrive.
6. Repeat.

V. Administer Naloxone
If the person is not breathing, perform rescue breathing for a few quick breaths first. Then, administer nasal or injectable Naloxone according to the instructions, which is better to read and know in advance.

VI. Aftercare
Naloxone only lasts between 30-90 minutes, while the effects of the opioids may last much longer. It is possible that after the naloxone wears off, the overdose could recur.

It is crucial that someone stays with the person and wait out the risk period just in case another dose of naloxone is necessary. Furthermore, because naloxone blocks opioids from acting, it is possible that it can cause withdrawal symptoms in someone that has a habit or physical dependence, daily opioid pain medication use, or other opioid tolerance. Someone who is taking opioids for daily pain management will go into withdrawal too and experience the pain that they are treating with the opioids.

Therefore, after giving someone naloxone, he or she may feel extremely sick and want to use it again right away. It is crucial that one does not use it again until the naloxone wears off so that a re-overdose does not occur.

Not only that, if the person uses more heroin or opioids when there is still naloxone in the system, he or she may not feel it at all – naloxone will knock it out of the opioid receptors and the person will have wasted their drugs. Try to support the person during this time period and encourage him or her not to use it for a couple of hours.

If the person cannot walk and talk well after waking up, then it is crucial that they are taken to the hospital.

If possible, stay with the person for several hours keeping them awake. It is safe to administer naloxone again if it is necessary. Note if a victim is not responsive to stimulation, not breathing, and has no pulse after receiving naloxone and rescue breathing, then the victim needs cardiopulmonary resuscitation (CPR) via a trained bystander and the emergency medical system. Call 911!

The rule

It is rare for someone to die immediately from an overdose. When people survive, it’s because someone was there to respond. The most important thing is to act right away.

You can find more details on the harmreduction.org. My material is largely inspired and borrows from their work. For example, this document is just below contains and competently presents detailed information about the help and prevention of opioid overdose.

That’s all for today.

If you think that something needs to be added or corrected in this article, please do not hesitate to reach out to me. I am always open to dialogue.

I hope this article was helpful. If you would like to support the development of this blog, please consider the following actions:

1. Subscribe to my social media accounts.
2. Share a link to this article with your friends.
3. Mention this blog on relevant resources or in chat groups.

Thank you for your time and attention

The post First aid for Opioid Overdose appeared first on Mindheal.